BPC-157 reduces pro-inflammatory cytokines including IL-6, TNF-alpha, and interferon-gamma while decreasing COX-2 gene expression
The 24-week trial is the longest controlled human study
A consultation is required
Many advocated that community health centers are eager to continue to enter into value-based care agreements, and this proposal will open the door to allow more to embark on this endeavor
Articular cartilage and joint health represent additional areas of therapeutic interest
Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7
